多西他赛联合顺铂同步放化疗治疗局部晚期鼻咽癌的临床观察.pdf

《多西他赛联合顺铂同步放化疗治疗局部晚期鼻咽癌的临床观察.pdf》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。

1、·1488·杨晓辉，等多西他赛联合顺铂同步放化疗治疗局部晚期鼻咽癌的临床观察多西他赛联合顺铂同步放化疗治疗局部晚期鼻咽癌的临床观察杨晓辉，蒋绍香，阮展鸿，朱前升，彭焱TheclinicalobservationofdocetaxelcombinedcisplatinwithconcurrentradiotherapyforthetreatmentoflocallyadvancednasopharyngealcarcinomaYangXiaohui，JiangShaoxiang，RuanZhanhong，ZhuQiansheng。，PengYanDep

2、artmentofOncology，TheLiuzhouSteelGroupHospital，GuangxiLiuzhou545002，China；DepartmentofOncology，ThePeopleHospitalofGuangxiZhuangAutonomousRegion，GuangxiNanning530021，China；DepartmentofInternalMedicine，TheLiuzhouSteelGroup'sHospita1．GuangxiLiuzhou545002．ina．【Abstract】0bjective：To

3、evaluatetheshort—termeficacyandadversereactionofdocetaxelcombinedcisplatinwithconcurrentradiotherapyforthetreatmentoflocallyadvancednasopharyngealcarcinoma．Methods：Toretrospec—tivelyanalyse42caseswithlocallyadvancednasopharyngealcarcinoma，whowerefirsttreatedbychemotherapyandcon

4、curentradiotherapy．Atthefirstandthefifthradiotherapyweek，allcasesreceivedtwocyclechemotherapy，therewere17casesinthegroup(TP)whoreceiveddocetaxelpluscisplatin[docetaxel75rag／nl，d1，cisplatin30mg／(in·d)，d1—3]，andtheanothergroup(PF)included25casesreceivedcisplatinplus5一fluorouraci(

5、cispl—atin30mIg／(m’d)，d13，fluorouracil750rag／(m·d)，d1Afterconventionalfractionradiotherapy，Theradiationdosewas66—78Gy／33—39timesinnasopharynx．and62—70Gy／31—35timesinnecklymphnodemetastasis．Re-suits：Thenasopharyngeallesioncompleteremissionrateandthenecklymphnodemetastasisremissi

6、oncompleteratewere82．35％(14／17)，88．24％(15／17)inTPgroup，whileinPFgroupwere76．O％(19／25)，84．0％(21／25)．The1一，2一yearsurvivalrateswere94．12％，82．35％inTPgroupand88．0％，76．0％inPFgroup，therewasnosignificantdifferencebetweenthetwogroup(P>0．05)．Buttherewasstatisticallysignificantdifferencei

7、nacuteoralmucositisandgastrointestinalreaction(P<0．05)．Conclusion：Theshort一艳啪eficacyofdocetaxelcombinedcis—platin(TP)withconcurentradiotherapyforthetreatmentoflocallyadvancednasopharyngealcarcinomaissatisfy，theadversereactionscanbetolerated．【Keywords】docetaxel；cisplatin；concurr

8、entchemotherapyandradiotherapy；nasopharyngealcarcinoma